Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1174

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1174
---
 such laws. If any such actions are instituted against Renovaro Cube or BioSymetrics, and either is
not successful in defending itself or asserting its rights, those actions could have a significant impact on each’s business, including
the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against Renovaro
Cube or BioSymetrics that either was not in violation of these laws, Renovaro Cube or BioSymetrics may be faced with negative publicity,
incur significant expenses defending its actions and have to divert significant management resources from other matters.

Risks Related To Our Business Operations

Our business plan may lead
to the initiation of one or more product development programs, the discontinuation of one or more development programs, or the execution
of one or more transactions that investors do not agree with or that investors do not perceive as favorable to their investment in our
Common Stock.

We are pursuing a strategy to,
dependent upon raising sufficient funding to do so, leverage our clinical experience and expertise for the clinical development and regulatory
approval of our gene therapy product candidates and advance our AI-driven healthcare technology. As part of our ongoing business strategy,
we continue to explore potential opportunities to acquire or license new product candidates and to collaborate on our existing products
in development. We cannot be certain that our product candidates will be successfully developed, or that the early clinical trial results
of our therapeutic product candidates will be predictive of future clinical trial results. During 2022, we decided to abandon our pan-coronavirus
and influenza pipelines as the results did not support further development. We again may determine at any time that one or more of our
in-licensed product candidates is not suitable for continued development due to cost, feasibility of obtaining regulatory approvals or
any other reason, and may terminate the related license.

Our business plan requires us
to be successful in a number of challenging, uncertain and risky activities, including pursuing development of our gene therapy product
candidates in indications for which we have limited or no human clinical data, designing and executing a nonclinical and/or clinical development
program for our product candidates, building internal or outsourced gene therapy capabilities, converting early stage gene therapy research
efforts into clinical development opportunities, identifying additional promising new assets for development that are available for acquisition
or in-license and that fit our strategic focus and identifying potential partners to collaborate on our products. We may not be successful
at one or more of the activities required for us to execute this business plan. In addition,